Biotechnology Companies By Book Value Per Share Ratio

Book Value Per Share
Book Value Per ShareEfficiencyMarket RiskExp Return
1GMAB Genmab AS
483.85
(0.11)
 2.10 
(0.23)
2REGN Regeneron Pharmaceuticals
242.47
 0.25 
 1.11 
 0.27 
3UTHR United Therapeutics
127.23
(0.05)
 1.63 
(0.09)
4BIIB Biogen Inc
102.14
(0.05)
 1.70 
(0.08)
5BNTX BioNTech SE
83.57
(0.08)
 2.18 
(0.17)
6VRTX Vertex Pharmaceuticals
68.22
 0.16 
 2.03 
 0.32 
7ARGX Argenx NV ADR
51.08
(0.06)
 3.86 
(0.23)
8ACOR Acorda Therapeutics
47.47
 0.10 
 4.72 
 0.48 
9AQB AquaBounty Technologies
45.02
 0.03 
 8.14 
 0.24 
10REVB Revelation Biosciences
42.01
(0.14)
 13.14 
(1.86)
11LGND Ligand Pharmaceuticals Incorporated
40.13
 0.16 
 3.36 
 0.52 
12GLPG Galapagos NV ADR
39.56
(0.08)
 1.72 
(0.13)
13TENX Tenax Therapeutics
37.84
(0.15)
 12.53 
(1.91)
14MRNA Moderna
36.27
 0.08 
 3.94 
 0.31 
15TIL Instil Bio
35.98
 0.24 
 4.21 
 1.02 
16BGNE BeiGene
33.83
(0.03)
 3.30 
(0.10)
17KRTX Karuna Therapeutics
32.94
 0.15 
 6.26 
 0.92 
18IMAB I Mab
29.48
 0.07 
 6.27 
 0.44 
19INCR INC Research Holdings
29.04
 0.16 
 5.19 
 0.83 
20CBUS Cibus Global LLC
27.82
 0.08 
 6.17 
 0.49 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation. The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.